These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35925597)

  • 1. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
    Madoff DC; Abi-Jaoudeh N; Braxton D; Goyal L; Jain D; Odisio BC; Salem R; Schattner M; Sheth R; Li D
    Oncologist; 2022 Oct; 27(10):884-891. PubMed ID: 35925597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.
    Capuozzo M; Santorsola M; Ferrara F; Cinque C; Farace S; Patrone R; Granata V; Zovi A; Nasti G; Ottaiano A
    Mol Cell Probes; 2024 Feb; 73():101951. PubMed ID: 38244704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices.
    Evans M; Kendall T
    Expert Rev Mol Diagn; 2024 May; 24(5):393-408. PubMed ID: 38752560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.
    European Association for the Study of the Liver
    J Hepatol; 2023 Jul; 79(1):181-208. PubMed ID: 37084797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach.
    Cho MT; Gholami S; Gui D; Tejaswi SL; Fananapazir G; Abi-Jaoudeh N; Jutric Z; Samarasena JB; Li X; Valerin JB; Mercer J; Dayyani F
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcentimetric Incidental Intrahepatic Cholangiocarcinoma in an Explant Liver: Diagnostic Difficulty of a Rare Entity.
    Mitra S; Geethanjali G; Rathi S; Behera A; Das A
    Int J Surg Pathol; 2018 Dec; 26(8):739-744. PubMed ID: 29742944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis of intrahepatic cholangiocarcinoma.
    Haga H; Patel T
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic cholangiocarcinoma: current management and emerging therapies.
    Rahnemai-Azar AA; Weisbrod AB; Dillhoff M; Schmidt C; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):439-449. PubMed ID: 28317403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
    J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.